These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
232 related articles for article (PubMed ID: 32992956)
1. Computational Study of C-X-C Chemokine Receptor (CXCR)3 Binding with Its Natural Agonists Chemokine (C-X-C Motif) Ligand (CXCL)9, 10 and 11 and with Synthetic Antagonists: Insights of Receptor Activation towards Drug Design for Vitiligo. Aguilera-Durán G; Romo-Mancillas A Molecules; 2020 Sep; 25(19):. PubMed ID: 32992956 [TBL] [Abstract][Full Text] [Related]
2. Modelling of the membrane receptor CXCR3 and its complexes with CXCL9, CXCL10 and CXCL11 chemokines: putative target for new drug design. Trotta T; Costantini S; Colonna G Mol Immunol; 2009 Dec; 47(2-3):332-9. PubMed ID: 19800124 [TBL] [Abstract][Full Text] [Related]
3. Dual specificity of anti-CXCL10-CXCL9 antibodies is governed by structural mimicry. Fagète S; Rousseau F; Magistrelli G; Gueneau F; Ravn U; Kosco-Vilbois MH; Fischer N J Biol Chem; 2012 Jan; 287(2):1458-67. PubMed ID: 22041899 [TBL] [Abstract][Full Text] [Related]
4. Role of chemokines CXCL9, CXCL10, CXCL11, and CXCR3 in the serum and minor salivary gland tissues of patients with Sjögren's syndrome. Kim JW; Ahn MH; Jung JY; Suh CH; Han JH; Kim HA Clin Exp Med; 2024 Jun; 24(1):133. PubMed ID: 38900301 [TBL] [Abstract][Full Text] [Related]
5. Small molecule chemokine mimetics suggest a molecular basis for the observation that CXCL10 and CXCL11 are allosteric ligands of CXCR3. Nedjai B; Li H; Stroke IL; Wise EL; Webb ML; Merritt JR; Henderson I; Klon AE; Cole AG; Horuk R; Vaidehi N; Pease JE Br J Pharmacol; 2012 Jun; 166(3):912-23. PubMed ID: 21895630 [TBL] [Abstract][Full Text] [Related]
6. CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. Tokunaga R; Zhang W; Naseem M; Puccini A; Berger MD; Soni S; McSkane M; Baba H; Lenz HJ Cancer Treat Rev; 2018 Feb; 63():40-47. PubMed ID: 29207310 [TBL] [Abstract][Full Text] [Related]
7. Molecular characterization of the chemokine receptor CXCR3: evidence for the involvement of distinct extracellular domains in a multi-step model of ligand binding and receptor activation. Xanthou G; Williams TJ; Pease JE Eur J Immunol; 2003 Oct; 33(10):2927-36. PubMed ID: 14515277 [TBL] [Abstract][Full Text] [Related]
8. The N-terminal region of CXCL11 as structural template for CXCR3 molecular recognition: synthesis, conformational analysis, and binding studies. Palladino P; Portella L; Colonna G; Raucci R; Saviano G; Rossi F; Napolitano M; Scala S; Castello G; Costantini S Chem Biol Drug Des; 2012 Aug; 80(2):254-65. PubMed ID: 22531000 [TBL] [Abstract][Full Text] [Related]
9. CXCR3 Ligands in Cancer and Autoimmunity, Chemoattraction of Effector T Cells, and Beyond. Karin N Front Immunol; 2020; 11():976. PubMed ID: 32547545 [TBL] [Abstract][Full Text] [Related]
10. Expression and regulation of the CXCL9-11 chemokines and CXCR3 receptor in Atlantic salmon Valdés N; Espinoza D; Pareja-Barrueto C; Olate N; Barraza-Rojas F; Benavides-Larenas A; Cortés M; Imarai M Front Immunol; 2024; 15():1455457. PubMed ID: 39301034 [TBL] [Abstract][Full Text] [Related]
11. Interleukin-27 and IFNγ regulate the expression of CXCL9, CXCL10, and CXCL11 in hepatitis. Basset L; Chevalier S; Danger Y; Arshad MI; Piquet-Pellorce C; Gascan H; Samson M J Mol Med (Berl); 2015 Dec; 93(12):1355-67. PubMed ID: 26199110 [TBL] [Abstract][Full Text] [Related]
12. Suction blistering the lesional skin of vitiligo patients reveals useful biomarkers of disease activity. Strassner JP; Rashighi M; Ahmed Refat M; Richmond JM; Harris JE J Am Acad Dermatol; 2017 May; 76(5):847-855.e5. PubMed ID: 28259440 [TBL] [Abstract][Full Text] [Related]
13. Label-free impedance responses of endogenous and synthetic chemokine receptor CXCR3 agonists correlate with Gi-protein pathway activation. Watts AO; Scholten DJ; Heitman LH; Vischer HF; Leurs R Biochem Biophys Res Commun; 2012 Mar; 419(2):412-8. PubMed ID: 22349504 [TBL] [Abstract][Full Text] [Related]
14. Intracellular domains of CXCR3 that mediate CXCL9, CXCL10, and CXCL11 function. Colvin RA; Campanella GS; Sun J; Luster AD J Biol Chem; 2004 Jul; 279(29):30219-27. PubMed ID: 15150261 [TBL] [Abstract][Full Text] [Related]
15. The IFN-γ-CXCL9/CXCL10-CXCR3 axis in vitiligo: Pathological mechanism and treatment. Liu H; Wang Y; Le Q; Tong J; Wang H Eur J Immunol; 2024 Apr; 54(4):e2250281. PubMed ID: 37937817 [TBL] [Abstract][Full Text] [Related]
16. Pharmacological characterization of a small-molecule agonist for the chemokine receptor CXCR3. Scholten DJ; Canals M; Wijtmans M; de Munnik S; Nguyen P; Verzijl D; de Esch IJ; Vischer HF; Smit MJ; Leurs R Br J Pharmacol; 2012 Jun; 166(3):898-911. PubMed ID: 21883151 [TBL] [Abstract][Full Text] [Related]
17. CCR3 functional responses are regulated by both CXCR3 and its ligands CXCL9, CXCL10 and CXCL11. Xanthou G; Duchesnes CE; Williams TJ; Pease JE Eur J Immunol; 2003 Aug; 33(8):2241-50. PubMed ID: 12884299 [TBL] [Abstract][Full Text] [Related]
18. Matrix metalloproteinase processing of CXCL11/I-TAC results in loss of chemoattractant activity and altered glycosaminoglycan binding. Cox JH; Dean RA; Roberts CR; Overall CM J Biol Chem; 2008 Jul; 283(28):19389-99. PubMed ID: 18411283 [TBL] [Abstract][Full Text] [Related]
19. Cross reactivity of three T cell attracting murine chemokines stimulating the CXC chemokine receptor CXCR3 and their induction in cultured cells and during allograft rejection. Meyer M; Hensbergen PJ; van der Raaij-Helmer EM; Brandacher G; Margreiter R; Heufler C; Koch F; Narumi S; Werner ER; Colvin R; Luster AD; Tensen CP; Werner-Felmayer G Eur J Immunol; 2001 Aug; 31(8):2521-7. PubMed ID: 11500837 [TBL] [Abstract][Full Text] [Related]
20. Analysis of cysteine-X-cysteine motif chemokine ligands 9, 10, and 11, their receptor CXCR3, and their possible role on the recruitment of immune cells at the maternal-conceptus interface in pigs. Han J; Gu MJ; Yoo I; Choi Y; Jang H; Kim M; Yun CH; Ka H Biol Reprod; 2017 Jul; 97(1):69-80. PubMed ID: 28859287 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]